Literature DB >> 17380459

[Chromosomal alterations analyzed by comparative genomic hybridization in primary gastric carcinoma].

Ya-qing Zhu1, Zheng-gang Zhu, Bing-ya Liu, Xue-hua Chen, Hao-ran Yin, Xue-hao Wang.   

Abstract

OBJECTIVE: To identify genetic abnormalities in primary gastric carcinoma.
METHODS: Comparative genomic hybridization (CGH) was used in screening DNA copy number changes along all chromosomes in 23 cases of primary gastric cancer.
RESULTS: Twenty-one out of 23 cases showed chromosomal losses and gains for at least one of the chromosomal arms in primary gastric cancer. The mean number of chromosomal alterations was 7.52. Chromosomal gains predominated over chromosomal losses in a ratio of 5.38:2.14. The most often involved chromosomal gains were observed in 8q (9/21, 42.9%), 20q (9/21, 42.9%), 17q (8/21, 38.1%), 3q (7/21, 33.3%), 7q (7/21, 33.3%), 11q (6/21, 28.6%), 13q (6/21, 28.6%), 1q (5/21, 23.8%) and 20p (5/21, 23.8%). The chromosomal arms with frequent losses were 17p (7/21, 33.3%), 18q (6/21, 28.6%), 5q (5/21, 23.8%), 8p (5/21, 23.8%), and 9p (5/21, 23.8%).
CONCLUSIONS: The phenomenon of gain and loss of chromosomal regions is observed in primary gastric cancer, which may induce the amplification of oncogenes and the loss of tumor suppressor genes to regulate the development and progression of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380459

Source DB:  PubMed          Journal:  Zhonghua Wei Chang Wai Ke Za Zhi        ISSN: 1671-0274


  1 in total

1.  Identification of IL11RA and MELK amplification in gastric cancer by comprehensive genomic profiling of gastric cancer cell lines.

Authors:  Danielle Queiroz Calcagno; Sylvia Santomi Takeno; Carolina Oliveira Gigek; Mariana Ferreira Leal; Fernanda Wisnieski; Elizabeth Suchi Chen; Taíssa Maíra Thomaz Araújo; Eleonidas Moura Lima; Maria Isabel Melaragno; Samia Demachki; Paulo Pimentel Assumpção; Rommel Rodriguez Burbano; Marília Cardoso Smith
Journal:  World J Gastroenterol       Date:  2016-11-21       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.